Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report

BACKGROUND: Catumaxomab, the first anti-EpCAM antibody, was approved in 2009 for the treatment of malignant ascites in cancer patients with EpCAM positive tumors. We consider this case of interest as treatment with catumaxomab not only prolonged the puncture-free interval but also showed a systemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bezan, Angelika, Hohla, Florian, Meissnitzer, Thomas, Greil, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880167/
https://www.ncbi.nlm.nih.gov/pubmed/24380380
http://dx.doi.org/10.1186/1471-2407-13-618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880167/
https://www.ncbi.nlm.nih.gov/pubmed/24380380
http://dx.doi.org/10.1186/1471-2407-13-618

Ejemplares similares